Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus DECADERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus DECADERM.
ARAZLO vs DECADERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Dexamethasone acts as a glucocorticoid receptor agonist, binding to the cytoplasmic glucocorticoid receptor, leading to modulation of gene transcription, suppression of pro-inflammatory cytokines, and induction of anti-inflammatory proteins, thereby reducing inflammation and immune responses.
Topical: Apply 0.045% gel once daily to affected areas of the face.
DECADERM (dexamethasone) is typically administered as 0.75-9 mg/day orally in divided doses every 6-12 hours, depending on the condition. For acute indications, higher doses (up to 40 mg/day) may be given intravenously or intramuscularly.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal elimination half-life approximately 36–54 hours (mean 44 h); prolonged in hepatic impairment.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Renal (primarily as inactive metabolites, <5% unchanged), fecal/biliary (<2%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid